NCT04074343已完成1 期
A Phase Ib Multicenter Study of TAS-102 in Combination With Irinotecan in Patients With Advanced Recurrent or Unresectable Gastric and Gastroesophageal Adenocarcinoma After at Least One Line of Treatment With a Fluoropyrimidine and Platinum Containing Regimen
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Percentage of Participants With Progression-free Survival at 6 Months
研究概览
简要总结
This is a phase Ib single-arm, open-label clinical trial determining the feasibility and efficacy of TAS-102 and irinotecan in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who are not candidates for curative treatments and who have received at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.
详细描述
Treatment on study will be administered in 14 day cycles.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically or cytologically confirmed gastric or gastroesophageal adenocarcinoma
- •Must have locally advanced, recurrent, or metastatic disease not amenable to curative intent surgery.
- •Must have progressed, or not tolerated, at least one line of treatment with a platinum and/or fluoropyrimidine containing regimen. At least one cycle of combination chemotherapy including a platinum (oxaliplatin, cisplatin, carboplatin) and/or fluoropyrimidine (capecitabine or 5-Fluorouracil) based regimen for advanced disease. Combination regimens with platinum/fluoropyrimidine containing a taxane and or a checkpoint inhibitor are allowed. Patients progressing within six months of perioperative chemotherapy or definitive chemoradiation for localized disease are eligible. Patients who have exhausted all other standard of care options are also eligible.
- •Age ≥ 18 years
- •Performance status: ECOG performance status ≤2
- •Life expectancy of greater than 3 months
- •Adequate organ and marrow function as defined below:
- •leukocytes : ≥ 3,000/mcL
- •absolute neutrophil count: ≥ 1,500/mcL
- •platelets: ≥ 80,000/mcl
- •total bilirubin: within normal institutional limits
- •AST(SGOT)/ALT(SPGT): ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present
- •creatinine: < 1.5 X upper limit of normal
- •The effects of TAS-102 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because topoisomerase inhibitors are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- •A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- •Has not undergone a hysterectomy or bilateral oophorectomy; or
- •Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
- •Ability to swallow tablets
- •Ability to understand and the willingness to sign a written informed consent.
排除标准
- •Patients who have had major surgery within 4 weeks, or chemotherapy or radiotherapy within 2 weeks prior to Cycle 1 Day
- •All toxicities attributed to prior anti-cancer therapy other than alopecia must have resolved to grade 1 or baseline
- •Patients may not be receiving any other investigational agents.
- •Patients with known brain metastases due to poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102, irinotecan or other agents used in study.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Prior treatment with irinotecan or TAS-102
- •History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ.
- •Inability to comply with study and follow-up procedures as judged by the Investigator
- •Patients who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
研究组 & 干预措施
TAS-102 and Irinotecan
Experimental
Patients receive TAS-102 25 mg/m2 PO twice daily on days 1-5 and and Irinotecan 180mg/m2 IV on day 1 every 14 days.
干预措施: TAS-102 (Drug)
TAS-102 and Irinotecan
Experimental
Patients receive TAS-102 25 mg/m2 PO twice daily on days 1-5 and and Irinotecan 180mg/m2 IV on day 1 every 14 days.
干预措施: Irinotecan (Drug)
结局指标
主要结局
Percentage of Participants With Progression-free Survival at 6 Months
时间窗: 6 Months
This is defined as the percentage of subjects who are free of progression 6 months after study treatment start. Progression is defined as death, radiographic progression or clinical deterioration attributed to disease progression as judged by an investigator. Radiographic progression is defined using the Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of diameters of target lesions and an absolute increase of an least 5 mm and/or appearance of new lesions.
次要结局
- Number of Participants With Grade 3-5 Adverse Events(8 Weeks)
- Objective Response Rate as Assessed by RECIST v1.1 Criteria of Patients Who Received TAS-102 and Irinotecan(From date of registration until first date of disease progression, toxicity, delay of treatment, or withdrawal of treatment, whichever came first, an average of 1 year.)
- Overall Survival of Patients of Patients Who Received TAS-102 and Irinotecan(From date of registration for up to 18 months after last patient is enrolled or until death from any cause, whichever came first.)
研究者
Farshid Dayyani
Associate Clinical Professor of Medicine
University of California, Irvine
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)Triple Negative Breast Cancer (TNBC)NCT06189209Rhizen Pharmaceuticals SA40
已完成
2 期
TAS-102 in Patients With Advanced, Refractory Pancreatic AdenocarcinomaPancreas CancerNCT04923529The University of Hong Kong28
已完成
2 期
A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1Advanced or Metastatic Non-small Cell Lung CancerNCT02855125Taiho Oncology, Inc.128
已完成
2 期
First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal CancerColorectal Cancer MetastaticNCT01163396Gruppo Oncologico del Nord-Ovest57
已完成
2 期
Study of CM310 in Patients With Allergic RhinitisAllergic RhinitisNCT05908721Keymed Biosciences Co.Ltd100